<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03692754</url>
  </required_header>
  <id_info>
    <org_study_id>Atorvastatin in ITP</org_study_id>
    <nct_id>NCT03692754</nct_id>
  </id_info>
  <brief_title>Atorvastatin in Management of Newly Diagnosed ITP</brief_title>
  <official_title>A Single-center Prospective Randomized Study of Atorvastatin in the Treatment of Newly Diagnosed Primary Immune Thrombocytopenia (ITP)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Shandong University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Shandong University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The project was undertaking by Qilu Hospital of Shandong University in China. In order to&#xD;
      report the efficacy and safety of atorvastatin for the treatment of adults with immune&#xD;
      thrombocytopenia (ITP).&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The investigators anticipate to undertaking a parallel group, single-centre, randomised&#xD;
      controlled trial of 30 ITP adult patients, which have no indications of glucocorticoid&#xD;
      therapy (platelets count &gt; 30*10^9/L )from Qilu Hospital of Shandong University in China.15&#xD;
      of the participants are randomly selected to receive atorvastatin in 20 mg/d combining with&#xD;
      10 mg/d for 6 months. Platelet count, bleeding and other symptoms were evaluated before and&#xD;
      after treatment, adverse events are also recorded throughout the study in order to report the&#xD;
      efficacy and safety of atorvastatin for the treatment of adults with ITP.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">November 1, 2021</start_date>
  <completion_date type="Anticipated">December 1, 2023</completion_date>
  <primary_completion_date type="Anticipated">December 1, 2021</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Evaluation of platelet response</measure>
    <time_frame>up to 1 year per subject</time_frame>
    <description>Platelet count will be observed at 1 month, 3 months, 6 months and 12 months after atorvastatin therapy</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Therapy associated adverse events</measure>
    <time_frame>up to 1 year per subject</time_frame>
    <description>The number and frequency of therapy associated adverse events</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Immune Thrombocytopenia</condition>
  <condition>Purpura, Thrombocytopenic</condition>
  <arm_group>
    <arm_group_label>AT with 10 mg/d</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>The patients will be given receive atorvastatin in 10 mg/d for 1 month plus dexamethasone 40mg/d for 4 days.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>AT with 20 mg/d</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>The patients will be given atorvastatin in 20 mg/d for 1 month plus dexamethasone 40mg/d for 4 days.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Dexamethasone</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The patients will be given dexamethasone 40mg/d for 4 days.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Atorvastatin 20mg</intervention_name>
    <description>Atorvastatin will be given in 20 mg po qn for 1 month</description>
    <arm_group_label>AT with 20 mg/d</arm_group_label>
    <other_name>atorvastatin calcium</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Atorvastatin 10mg</intervention_name>
    <description>Atorvastatin will be given in 10 mg po qn for 1 month</description>
    <arm_group_label>AT with 10 mg/d</arm_group_label>
    <other_name>atorvastatin calcium</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dexamethasone</intervention_name>
    <description>Dexamethasone will be given in 40mg po qd for 4 days</description>
    <arm_group_label>AT with 10 mg/d</arm_group_label>
    <arm_group_label>AT with 20 mg/d</arm_group_label>
    <arm_group_label>Dexamethasone</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Meet the diagnostic criteria for immune thrombocytopenia.&#xD;
&#xD;
          2. within 3 months from diagnosis,untreated patients, may be male orfemale, between the&#xD;
             ages of 18 ~ 80 years.&#xD;
&#xD;
          3. To show a platelet count &gt; 30Ã—10^9/L and without bleeding manifestations.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Received chemotherapy or anticoagulants or other drugs affecting theplatelet counts&#xD;
             within 3 months before the screening visit.&#xD;
&#xD;
          2. Received steroids or other effective therapy for immune thrombocytopenia.&#xD;
&#xD;
          3. Current HIV infection or hepatitis B virus or hepatitis C virus infections.&#xD;
&#xD;
          4. Severe medical condition (lung, hepatic or renal disorder) other than ITP.&#xD;
&#xD;
          5. Unstable or uncontrolled disease or condition related to or impacting cardiac function&#xD;
             (e.g., unstable angina, congestive heart failure, uncontrolled hypertension or cardiac&#xD;
             arrhythmia)&#xD;
&#xD;
          6. Female patients who are nursing or pregnant, who may be pregnant, or who contemplate&#xD;
             pregnancy during the study period.&#xD;
&#xD;
          7. Have a known diagnosis of other autoimmune diseases, established in the medical&#xD;
             history and laboratory findings with positive results for the determination of&#xD;
             antinuclear antibodies, anti-cardiolipin antibodies, lupus anticoagulant or direct&#xD;
             Coombs test.&#xD;
&#xD;
          8. Patients who are deemed unsuitable for the study by the investigator.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ming Hou, Dr</last_name>
    <role>Principal Investigator</role>
    <affiliation>Shandong University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Ming Hou, Dr</last_name>
    <phone>+86-531-82169114</phone>
    <phone_ext>9879</phone_ext>
    <email>houming@medmail.com.cn</email>
  </overall_contact>
  <location>
    <facility>
      <name>Qilu hospital, Shandong University</name>
      <address>
        <city>Jinan</city>
        <state>Shandong</state>
        <zip>250012</zip>
        <country>China</country>
      </address>
    </facility>
    <contact>
      <last_name>Ming Hou</last_name>
      <email>houming@medmail.com.cn</email>
    </contact>
    <investigator>
      <last_name>Ming Hou</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>September 29, 2018</study_first_submitted>
  <study_first_submitted_qc>September 29, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">October 2, 2018</study_first_posted>
  <last_update_submitted>August 30, 2021</last_update_submitted>
  <last_update_submitted_qc>August 30, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 5, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Shandong University</investigator_affiliation>
    <investigator_full_name>Ming Hou</investigator_full_name>
    <investigator_title>Professor and Director</investigator_title>
  </responsible_party>
  <keyword>Immune Thrombocytopenia</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Thrombocytopenia</mesh_term>
    <mesh_term>Purpura</mesh_term>
    <mesh_term>Purpura, Thrombocytopenic, Idiopathic</mesh_term>
    <mesh_term>Purpura, Thrombocytopenic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Calcium, Dietary</mesh_term>
    <mesh_term>Dexamethasone</mesh_term>
    <mesh_term>Atorvastatin</mesh_term>
    <mesh_term>Calcium</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

